X

Drug Profile

VIR 7229

Alternative Names: VIR-7229

Latest Information Update: 08 May 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vir Biotechnology
Class Antivirals; Monoclonal antibodies
Mechanism of Action Virus internalisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical COVID 2019 infections

Most Recent Events

08 May 2024 In May 2024, Vir Biotechnology announced the intentions to file IND for COVID-2019 infections within next 18 months
02 Nov 2023 Vir Biotechnology plans a phase I trial in COVID-2019 infections in 2024
08 Aug 2023 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) before August 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com